Literature DB >> 28465548

Helicobacter pylori infection and antibiotic resistance: a WHO high priority?

Bich N Dang1, David Y Graham2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28465548      PMCID： PMC6905073          DOI： 10.1038/nrgastro.2017.57

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  6 in total

1.  Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.

Authors:  P Malfertheiner; F Megraud; C A O'Morain; J P Gisbert; E J Kuipers; A T Axon; F Bazzoli; A Gasbarrini; J Atherton; D Y Graham; R Hunt; P Moayyedi; T Rokkas; M Rugge; M Selgrad; S Suerbaum; K Sugano; E M El-Omar
Journal:  Gut       Date:  2016-10-05       Impact factor: 23.059

2.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

Authors:  William D Chey; Grigorios I Leontiadis; Colin W Howden; Steven F Moss
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

Review 3.  Treating Helicobacter pylori effectively while minimizing misuse of antibiotics.

Authors:  Akiko Shiotani; Hong Lu; Maria Pina Dore; David Y Graham
Journal:  Cleve Clin J Med       Date:  2017-04       Impact factor: 2.321

4.  Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.

Authors:  Qi Chen; Wei Zhang; Qingyan Fu; Xiao Liang; Wenzhong Liu; Shudong Xiao; Hong Lu
Journal:  Am J Gastroenterol       Date:  2016-09-27       Impact factor: 10.864

5.  The Toronto Helicobacter pylori Consensus in Context.

Authors:  David Y Graham; Loren Laine
Journal:  Gastroenterology       Date:  2016-05-20       Impact factor: 22.682

Review 6.  Helicobacter pylori therapy: a paradigm shift.

Authors:  David Y Graham; Maria Pina Dore
Journal:  Expert Rev Anti Infect Ther       Date:  2016-05-03       Impact factor: 5.091
  6 in total
  35 in total

1.  It is time to rethink H. pylori therapy.

Authors:  Bich N Dang; David Y Graham
Journal:  J Gastrointestin Liver Dis       Date:  2017-06       Impact factor: 2.008

2.  Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI.

Authors:  David Y Graham; Hong Lu; Maria Pina Dore
Journal:  Helicobacter       Date:  2018-11-15       Impact factor: 5.753

Review 3.  Leveraging laboratory and clinical studies to design effective antibiotic combination therapy.

Authors:  Kathleen Davis; Talia Greenstein; Roberto Viau Colindres; Bree B Aldridge
Journal:  Curr Opin Microbiol       Date:  2021-10-08       Impact factor: 7.934

Review 4.  Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  Clin Microbiol Rev       Date:  2022-04-11       Impact factor: 50.129

5.  Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States.

Authors:  Hashem B El-Serag; John Y Kao; Fasiha Kanwal; Mark Gilger; Frank LoVecchio; Steven F Moss; Sheila E Crowe; Adam Elfant; Thomas Haas; Ronald J Hapke; David Y Graham
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-17       Impact factor: 11.382

6.  Reply.

Authors:  Hashem B El-Serag; David Y Graham
Journal:  Clin Gastroenterol Hepatol       Date:  2018-12       Impact factor: 11.382

7.  Horizontal gene transfer potentiates adaptation by reducing selective constraints on the spread of genetic variation.

Authors:  Laura C Woods; Rebecca J Gorrell; Frank Taylor; Tim Connallon; Terry Kwok; Michael J McDonald
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-14       Impact factor: 11.205

Review 8.  Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.

Authors:  David Y Graham; Maria Pina Dore; Hong Lu
Journal:  Expert Rev Anti Infect Ther       Date:  2018-08-23       Impact factor: 5.091

Review 9.  Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship.

Authors:  David Y Graham; Jyh-Ming Liou
Journal:  Clin Gastroenterol Hepatol       Date:  2021-03-26       Impact factor: 13.576

10.  Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.

Authors:  Hidetaka Okubo; Junichi Akiyama; Masao Kobayakawa; Megumi Kawazoe; Saori Mishima; Yusuke Takasaki; Naoyoshi Nagata; Takayuki Shimada; Chizu Yokoi; Shiori Komori; Kana Kimura; Yuya Hisada; Eri Iwata; Kazuhiro Watanabe; Naohiro Yanagisawa; Sho Shiroma; Akira Shimomura; Koki Okahara; Hourin Cho; Naomi Uemura
Journal:  J Gastroenterol       Date:  2020-09-15       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.